Patent intelligence · WO
WO 2020094634
PROMÉDICAMENTS DE THIOPHÈNE DE NALTROXÈNE POUR COMPOSITIONS INJECTABLES À ACTION PROLONGÉE ET PROCÉDÉS ASSOCIÉS
PROMÉDICAMENTS DE THIOPHÈNE DE NALTROXÈNE POUR COMPOSITIONS INJECTABLES À ACTION PROLONGÉE ET PROCÉDÉS ASSOCIÉS
Patent details — WO 2020094634
- Jurisdiction
- WO
- Status
- granted
- Grant date
- May 14, 2020
- Expiration
- May 9, 2040
- Applicant
- ALKERMES PHARMA IRELAND LTD [IE]
- CPC classes
- A61K 31/ 485 A I, A61K/31485, A61P 25/ 30 A I, A61P/2530
Quick answer
WO 2020094634 (PROMÉDICAMENTS DE THIOPHÈNE DE NALTROXÈNE POUR COMPOSITIONS INJECTABLES À ACTION PROLONGÉE ET PROCÉDÉS ASSOCIÉS) is held by ALKERMES PHARMA IRELAND LTD [IE]. Status: granted. Granted May 14, 2020. Expires May 9, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ALKERMES PHARMA IRELAND LTD [IE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 485 A I, A61K/31485, A61P 25/ 30 A I, A61P/2530
More from ALKERMES PHARMA IRELAND LTD [IE]
Related pharmaceutical patents in our USPTO index.
-
AU 2022263543
Pharmaceutical compositions comprising sorbitan esters
granted -
US 2023302008
METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM IN A BOLUS DOSE
granted -
WO 2023156493
FORMES CRISTALLINES DE NALTREXONE
granted -
WO 2023154894
COMPOSITIONS ET PROCÉDÉS D'IMMUNOTHÉRAPIE ANTICANCÉREUSE
granted -
CY 2022006
ΠΡΟΦΑΡΜΑΚΑ ΦΟΥΜΑΡΙΚΩΝ ΑΛΑΤΩΝ ΚΑΙ Η ΧΡΗΣΗ ΤΟΥΣ ΣΤΗΝ ΑΓΩΓΗ ΠΟΙΚΙΛΩΝ ΝΟΣΩΝ
granted -
US 2022354866
IMMEDIATE RELEASE MULTILAYER TABLET
granted -
CA 3172871
COMPOSITIONS DE POLYPEPTIDES DE FUSION D'IL-2 ET LEURS PROCEDES DE FABRICATION ET D'UTILISATION
granted -
CA 3172874
COMPOSITIONS DE POLYPEPTIDES DE FUSION D'IL-2 ET LEURS PROCEDES DE FABRICATION ET D'UTILISATION
granted
Frequently asked questions
What is US patent 2020094634?
WO 2020094634 (PROMÉDICAMENTS DE THIOPHÈNE DE NALTROXÈNE POUR COMPOSITIONS INJECTABLES À ACTION PROLONGÉE ET PROCÉDÉS ASSOCIÉS) is held by ALKERMES PHARMA IRELAND LTD [IE]. Status: granted. Granted May 14, 2020. Expires May 9, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns WO 2020094634?
ALKERMES PHARMA IRELAND LTD [IE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does WO 2020094634 expire?
Our index shows an expiration date of May 9, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.